In a new op-ed for Roll Call, U.S. Senator Rand Paul (R-KY), Ranking Member of the Senate Homeland Security and Governmental Affairs Committee, discussed the need to reexamine the government’s classification process and increase transparency.
Dr. Paul Stresses Need to Overhaul Government Classification Process and Increase Transparency
WASHINGTON, D.C. – Today, U.S. Senator Rand Paul (R-KY), Ranking Member of the Senate Homeland Security and Governmental Affairs Committee, stressed the urgent need to fix the government’s classification processes at a committee hearing titled “Modernizing the Government’s Classification System.” The hearing examined the government’s excessive classification of documents and information over the last several decades.
Dr. Rand Paul, Rep. Chip Roy Introduce NIH Reform Act
WASHINGTON, D.C. – Today, U.S. Senator and physician Rand Paul (R-KY) and U.S. Representative Chip Roy. (R-TX-21) introduced the NIH Reform Act to eliminate Dr. Anthony Fauci’s National Institute of Allergy and Infectious Diseases (NIAID) and replace it with three separate national research institutes that would be led by directors subject to Senate confirmation and limited to no more than two 5-year terms.
Dr. Rand Paul Continues Efforts to Return War Powers to Congress, Forces Senate Vote on Amendment to Repeal 2001 AUMF
WASHINGTON, D.C. – Today, U.S. Senator Rand Paul (R-KY), Ranking Member of the Senate Homeland Security and Governmental Affairs Committee, continued his longtime efforts to return war making powers to Congress by forcing the Senate to vote on his amendment to repeal the 2001 Authorization for Use of Military Force (AUMF). The final vote tally was 9-86.
At Hearing, Dr. Paul Addresses the Dangers of the Government’s Heavy Hand in Drug Shortages
FOR IMMEDIATE RELEASE:March 22, 2023Contact: Press_Paul@paul.senate.gov, 202-224-4343 At Hearing, Dr. Paul Addresses The Dangers of the Government's Heavy Hand in Drug Shortages WASHINGTON, D.C. – Today, U.S. Senator Rand Paul (R-KY), Ranking Member of the Senate...
Dr. Rand Paul Continues Efforts to Return War Powers to Congress, Introduces Amendment to Repeal 2001 AUMF
Today, U.S. Senator Rand Paul (R-KY), Ranking Member of the Senate Homeland Security and Governmental Affairs Committee, continued his longtime efforts to return war making powers to Congress by introducing an amendment to repeal the 2001 Authorization for Use of Military Force (AUMF).
Dr. Rand Paul Reintroduces Bonuses for Cost-Cutters Act
WASHINGTON, D.C. – Today, U.S. Senator Rand Paul (R-KY), Ranking Member of the Senate Homeland Security and Governmental Affairs Committee, continued his efforts to rein in wasteful spending and reform government by reintroducing the Bonuses for Cost-Cutters Act.
Dr. Paul, Sen. Hassan Introduce Duplication Scoring Act
WASHINGTON, D.C. – Today, U.S. Senator Rand Paul (R-KY), Ranking Member of the Senate Homeland Security and Governmental Affairs Committee, and U.S. Senator Maggie Hassan (D-NH) introduced the Duplication Scoring Act, which seeks to reduce the size of government by eliminating duplicative programs and prevent further duplication within the federal government.
Dr. Paul, Sen. Hassan Introduce Bipartisan Bill to Lower Health Care Costs by Streamlining Generic Medication Approval Process
WASHINGTON, D.C. – Today, U.S. Senators Rand Paul (R-KY) and Maggie Hassan (D-NH), both members of the Health, Education, Labor, and Pensions Committee, reintroduced bipartisan legislation to streamline the approval process for generic medications, which are often significantly cheaper than their brand-name counterparts. The bipartisan Increasing Transparency in Generic Drug Applications Act would help get generic medications onto the market faster and lower prescription drug prices for consumers.
Dr. Paul, Sen. Booker Introduce Bipartisan Legislation to Promote Research and Access to Potential Life Saving Drugs
WASHINGTON, D.C. – Today, U.S. Senators Rand Paul (R-KY) and Cory Booker (D-NJ) introduced an updated version of the Breakthrough Therapies Act. This legislation will remove regulatory hurdles that inhibit research and compassionate use access to potentially lifesaving treatments that are heavily restricted by Schedule I of the Controlled Substances Act.